Since SHP2 inhibition augmented PD-L1 expression in cancer cells in co-culture with T cells, we combined SHP2 blockade with immune checkpoint inhibition and the combo showed combinatorial benefit on boosting anti-tumor immunity and slowing down tumor growth. Here, PTPN11 is linked to cancer.